BNP-105 is under clinical development by EMS and currently in Phase I for Aphthous Ulcers (Canker Sores). According to GlobalData, Phase I drugs for Aphthous Ulcers (Canker Sores) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BNP-105 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BNP-105 overview

BNP-105 is under development for the treatment of recurrent aphthous stomatitis. The drug candidate is administered through oral route in the form of suspension.

EMS overview

EMS, a subsidiary of Grupo NC, is a pharmaceutical company that focuses on the development of products for the improvement of the health and well-being of the population. The company operates in the segments of medical prescription, generics, branded pharmaceuticals, manufacturing products, OTC, and hospitals. Its major product portfolio includes drugs in the therapeutic areas of anti-inflammatories, analgesics, antihypertensives, anthelmintics, antidiabetics, antibiotics, topical corticosteroids, anti-ulcers, and anti-flu. EMS has production units in Sao Bernardo do Campo, Jaguariuna and Hortolandia in Sao Paulo; Novamed, Manaus in Amazonas; and Brasilia in Federal District. The company is certified by European Medicines Agency. EMS is headquartered in Hortolandia, Brazil.

For a complete picture of BNP-105’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.